Kaya Holdings, Inc. Market Research Report

Background

Company Overview

Kaya Holdings, Inc. is a vertically integrated legal cannabis enterprise based in Fort Lauderdale, Florida. The company operates in the United States, focusing on the production, distribution, and sale of premium cannabis products, including flower, oils, vape cartridges, and cannabis-infused edibles and beverages. Additionally, Kaya Holdings provides medical and recreational cannabis, as well as cannabidiol (CBD) products. The company also operates retail outlets under the Kaya Shack™ brand and offers strain-specific cannabis cigarettes under the Kaya Buddie™ name and various cannabis strains under the Kaya Farms™ name. In September 2024, Kaya Holdings opened The Sacred Mushroom™, a psychedelic treatment center in Portland, Oregon, providing access to psilocybin treatments.

Mission and Vision

Kaya Holdings is committed to enhancing wellness and mental health through innovative treatments, including psychedelic therapy, while maintaining a strong presence in the legal cannabis industry. The company's mission is to provide high-quality, accessible, and effective products and services that promote overall well-being.

Primary Area of Focus

The company's primary focus areas include:

• Psychedelic Therapy: Developing and operating licensed psilocybin treatment centers to offer alternative mental health treatments.

• Cannabis Production and Retail: Cultivating, processing, and selling a range of cannabis products through owned and operated dispensaries.

• CBD Products: Producing and distributing cannabidiol-based products for various therapeutic applications.

Industry Significance

Kaya Holdings operates in the rapidly evolving legal cannabis and psychedelic therapy sectors, both of which have experienced significant growth and regulatory changes in recent years. The company's integrated approach positions it as a notable player in these industries, contributing to the expansion and acceptance of alternative wellness treatments.

Key Strategic Focus

Core Objectives

• Expansion of Psychedelic Therapy Services: Establish and operate additional licensed psilocybin treatment centers to meet growing demand for alternative mental health treatments.

• Diversification of Product Offerings: Broaden the range of cannabis and CBD products to cater to a wider consumer base.

• Geographic Expansion: Explore opportunities to enter new markets, both domestically and internationally, leveraging favorable regulatory environments.

Specific Areas of Specialization

• Psilocybin Treatment Centers: Developing facilities that provide access to psilocybin-based therapies for mental health conditions.

• Cannabis Cultivation and Processing: Engaging in the cultivation, processing, and distribution of cannabis products, ensuring quality and compliance with regulations.

• CBD Product Development: Creating a diverse portfolio of CBD products for therapeutic and wellness purposes.

Key Technologies Utilized

• Cultivation Technologies: Implementing advanced agricultural practices and technologies to optimize cannabis cultivation.

• Extraction Methods: Utilizing state-of-the-art extraction techniques to produce high-quality cannabis concentrates and CBD products.

• Psychedelic Therapy Protocols: Developing and adhering to evidence-based protocols for psilocybin-assisted therapy sessions.

Primary Markets Targeted

• Domestic Markets: Focusing on states with legalized medical and recreational cannabis, as well as regions where psychedelic therapy is gaining acceptance.

• International Markets: Exploring opportunities in countries with favorable regulations for cannabis and psychedelic treatments.

Financials and Funding

Funding History

Kaya Holdings has engaged in multiple funding rounds to support its operations and expansion initiatives. In 2024, the company raised approximately $615,000 through private debt and equity offerings, compared to $370,000 in 2023.

Total Funds Raised

The company has raised a total of approximately $985,000 over the past two years to fund its strategic initiatives.

Notable Investors

Specific details regarding individual investors are not publicly disclosed.

Intended Utilization of Capital

• Psychedelic Therapy Expansion: Funding the development and operation of additional psilocybin treatment centers.

• Product Development: Investing in the creation and marketing of new cannabis and CBD products.

• Operational Costs: Covering expenses related to cultivation, processing, and retail operations.

Pipeline Development

Key Pipeline Candidates

• Psilocybin Treatment Centers: The Sacred Mushroom™ in Portland, Oregon, is the flagship facility, with plans for additional centers in other states.

• Cannabis Cultivation Facilities: Development of an 85,000-square-foot greenhouse facility in Lebanon, Oregon, with a production capacity of approximately 100,000 pounds annually.

Stages of Clinical Trials or Product Development

• Psilocybin Therapy: The Sacred Mushroom™ began operations in September 2024, offering psilocybin-assisted therapy sessions.

• Cannabis Products: Ongoing development and refinement of various cannabis strains and CBD products for market introduction.

Target Conditions

• Psilocybin Therapy: Mental health conditions such as depression, anxiety, and PTSD.

• Cannabis Products: General wellness, pain management, and specific therapeutic applications.

Relevant Timelines for Anticipated Milestones

• Psilocybin Treatment Centers: Expansion plans include opening additional centers in 2025 and 2026, pending regulatory approvals.

• Cannabis Cultivation Facility: Construction of the Lebanon, Oregon facility is expected to commence in 2025, with production slated to begin in 2026.

Technological Platform and Innovation

Proprietary Technologies

• Cultivation Techniques: Utilizing hydroponic systems and climate-controlled environments to optimize plant growth and yield.

• Extraction Processes: Employing CO₂ extraction methods to produce pure and potent cannabis concentrates.

Significant Scientific Methods

• Psychedelic Therapy Protocols: Implementing structured therapy sessions combining psilocybin administration with psychological support.

• Product Development: Conducting research to develop unique cannabis strains and formulations tailored to specific therapeutic needs.

Leadership Team

Key Executive Profiles

• Craig R. Frank: Chairman, President, Chief Executive Officer, and Acting Chief Financial Officer. Craig has extensive experience in the cannabis industry and has been instrumental in leading Kaya Holdings' strategic direction.

• David A. Levine: Chief Compliance and Security Advisor. David oversees regulatory compliance and security measures, ensuring the company's operations adhere to legal standards.

• Chad Craig: Senior Vice President of Oregon Operations. Chad manages the company's operations in Oregon, focusing on the development and management of retail dispensaries and cultivation facilities.

Leadership Changes

• Richard D. Seay: Appointed as a new director, effective November 25, 2025. Richard brings extensive experience in corporate governance and strategic planning.

Competitor Profile

Market Insights and Dynamics

The legal cannabis and psychedelic therapy markets are experiencing rapid growth, driven by changing public perceptions and evolving regulatory landscapes. Kaya Holdings faces competition from both established companies and new entrants aiming to capitalize on these expanding markets.

Competitor Analysis

• Versea Holdings: A pharmaceutical company focused on developing molecules for treating inflammatory and other debilitating diseases.

• AXIM Biotechnologies: Specializes in the research, development, and production of cannabis-based pharmaceutical, nutraceutical, and cosmetic products.

• Harvest Health and Recreation: Engages in cannabis processing, cultivation, and sale, operating in multiple states.

Strategic Collaborations and Partnerships

Kaya Holdings has engaged advisors such as Greentree Financial Group and Conduit Advisors to assist in developing a cryptocurrency subsidiary and implementing a digital assets treasury strategy.

Operational Insights

Kaya Holdings' integrated approach, combining cannabis production, retail, and psychedelic therapy services, differentiates it from competitors. The company's focus on quality, compliance, and innovation positions it to capitalize on emerging market opportunities.

Strategic Opportunities and Future Directions

Strategic Roadmap

• Expansion of Psychedelic Therapy Services: Establish additional treatment centers in states where psilocybin therapy is legal.

• Diversification of Product Lines: Develop new cannabis and CBD products to meet diverse consumer preferences.

• International Expansion: Leverage international subsidiaries to enter European markets, particularly Greece and Israel, for cannabis cultivation and processing.

Future Business Directions

Kaya Holdings aims to become a leading provider of alternative wellness treatments and premium cannabis products, focusing on quality, compliance, and customer experience.